[1] XU J, LIU Y, LI Y, et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer[J]. Nat Nanotechnol, 2019, 14(4): 388. doi: 10.1038/s41565-019-0381-6
[2] XIAO W, LI X, YANG A, et al. Analysis of prognostic factors affecting the brain metastases free survival and survival after brain metastases in breast cancer[J]. Front Oncol, 2020, 10: 431. doi: 10.3389/fonc.2020.00431
[3] EFSTATHIOU JA, MOUW KW, GIBB EA, et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer[J]. Eur Urol, 2019, 76(1): 59. doi: 10.1016/j.eururo.2019.01.011
[4] VAGIA E, MAHALINGAM D, CRISTOFANILLI M. The landscape of targeted therapies in TNBC[J]. Cancers(Basel), 2020, 12(4): 916.
[5] LANDRY BD, LEETE T, RICHARDS R, et al. Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells[J]. Mol Syst Biol, 2018, 14(8): e8322.
[6] JIN R, ZHAO J, XIA L, et al. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench[J]. Ther Adv Med Oncol, 2020, 12: 1758835920930333.
[7] RAVELLI A, ROVIELLO G, CRETELLA D, et al. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility[J]. Tumour Biol, 2017, 39(4): 1010428317695023.
[8] PRUNERI G, GRAY KP, VINGIANI A, et al. Tumor-infiltrating lymphocytes(TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase Ⅲ randomized clinical trial 22-00[J]. Breast Cancer Res Treat, 2016, 158(2): 323. doi: 10.1007/s10549-016-3863-3
[9] BLACKLEY EF, LOI S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer(TNBC)[J]. Breast, 2019, 48: S44.
[10] VIHERVUORI H, AUTERE TA, REPO H, et al. Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer[J]. J Cancer Res Clin Oncol, 2019, 145(12): 3105. doi: 10.1007/s00432-019-03036-5
[11] KURODA H, JAMIYAN T, YAMAGUCHI R, et al. Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer[J]. Breast Cancer, 2021, 28(4): 904. doi: 10.1007/s12282-021-01227-y
[12] GAO G, WANG Z, QU X, et al. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis[J]. BMC Cancer, 2020, 20(1): 179. doi: 10.1186/s12885-020-6668-z
[13] KURODA H, JAMIYAN T, YAMAGUCHI R, et al. Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast[J]. BMC Cancer, 2021, 21(1): 286. doi: 10.1186/s12885-021-08009-x
[14] 祝景伟, 孟超, 佟经伟, 等. p53和TAZ在三阴性乳腺癌中的表达和意义[J]. 蚌埠医学院学报, 2021, 46(4): 517.
[15] 阮吟, 石彦, 宁艳, 等. 常规超声BI-RADS分类结合实时剪切波弹性成像对三阴性乳腺癌的诊断价值[J]. 蚌埠医学院学报, 2020, 45(5): 630.